The Boston-based company said it had a loss of 14 cents per share.
The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 13 cents per share.
The biopharmaceutical company posted revenue of $28 million in the period, which also fell short of Street forecasts. Three analysts surveyed by Zacks expected $29.6 million.
The company's shares closed at $3.03. A year ago, they were trading at $5.08.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on KERX at https://www.zacks.com/ap/KERX
Copyright 2019 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.